Acute promyelocytic leukemia (APL) is highly aggressive and is frequently associated with disseminated intravascular coagulation and high early death rates. Although all-trans retinoic acid (RA) induces complete remission in a high proportion of patients with APL, there are limited treatments for APL patients with RA resistance. Here we report an atypical APL patient, with an APL-like disease that developed very slowly without anti-leukemia therapy for nearly 2 years. During that time, the patient only intermittently received anti-HBV drugs, i.e., the combination of adefovir dipivoxil (ADV) and entecavir (ETV), leading us to hypothesize that ADV and/or ETV could inhibit APL progression. Our results showed that anti-HBV drugs ADV and ETV both exhibited significantly inhibitory effects on APL cells, and ADV indicated a much greater cytotoxic effect than ETV on APL cells. We further found that ADV significantly promoted APL cell differentiation and apoptosis, thereby restraining the progression of APL. Most importantly, our study uncovered a novel mechanism of ADV prohibiting APL progression, which was mediated, at least in part, by inhibition of TRIB3 and degradation of the oncoprotein PML-RARA, therefore leading to APL cell differentiation and apoptosis. Taken together, our study demonstrated that ADV, an anti-HBV drug, had significantly inhibitory effects on APL, and provided a novel therapeutic strategy for APL patients with RA resistance.
To the editor,
Acute promyelocytic leukemia (APL) is highly aggressive, and the disease may occur abruptly, with a relatively high early death rate (up to 30%) associated with coagulopathy [1,2,3]. Here we report an atypical APL case. The patient, treated with anti-HBV drugs, showed a very slowly progressing APL-like disease. Since this patient had never been treated with all-trans retinoic acid or chemotherapy, we hypothesized that anti-HBV drugs, i.e., adefovir dipivoxil (ADV) and/or entecavir (ETV), could inhibit APL progression. Our results showed that ADV exhibited significantly inhibitory effects on APL.
The patient had a long history of hepatitis B virus (HBV) infection for more than 40 years. Since 2017, the patient had been treated with anti HBV drugs intermittently. The 1st bone marrow (BM) examination was performed due to low white blood cells and platelets, and BM smears showed 9.0% abnormal promyelocytes, bundles of Auer rods were present (Fig. 1A). The patient was not given anti-leukemia therapy. The 2nd BM examination was performed 7 months later, and BM smears showed 11.0% abnormal promyelocytes and BM biopsies revealed decreased BM hyperplasia (Fig. 1B). Flow cytometry showed a low proportion of abnormal myeloid cells (1.5%) within CD45+ cells, which also expressed CD9, CD13, CD33, CD38, CD64, CD117, CD123, but not CD15, CD34, or HLA-DR (Fig. 1D). Cytogenetic analysis of BM cells revealed 46, XY, and the Bcr1 type of PML-RARA fusion was negative.
The patient had been monitored for another 15 months without anti-leukemia therapy, and then the 3rd BM examination was performed. Abnormal promyelocytes were increased on BM smears (34.0%) and biopsies (Fig. 1C, E). It showed a Bcr3 type of PML-RARA. Therefore, at this time, the patient was diagnosed as APL with PML-RARA (Additional file 1: Table S1). After treatment with all-trans-retinoic-acid and arsenic trioxide, the patient achieved complete remission.
APL, without therapy, progresses quickly with a high risk of mortality. It is very unusual that the patient has lived for more than 22 months without anti-leukemia therapy. During that time, she only received anti-HBV drugs, i.e., the combination of ADV (10 mg/d), and ETV (0.5 mg/d) intermittently, which had been discontinued for nearly 3 months due to the pandemic of Corona Virus. Therefore we speculated that the very slow progression of APL may be associated with the treatment with anti-HBV drugs.
We next determined whether ADV or ETV contributed to APL inhibition. Both ADV and ETV were nucleoside/ nucleotide analogs, but our results using cell counting kit-8 (CCK-8) assay showed that ADV seemed to have stronger cytotoxic effect than ETV on APL cells (Fig. 1F). A significant increase of apoptosis rates was observed in APL cell line NB4 and AML-M2 cell line HL-60 treated with 5 µM ADV for 24 h analysed with TUNEL assay, but not in counterparts treated with 5 µM ETV (Fig. 1G, Additional file 1: Fig. S1A). Morphological changes of apoptosis were evident with Wright-Giemsa staining (Fig. 1H), and PARP was clearly cleaved in the presence of ADV (Fig. 2A). Thus, ADV showed a greater inhibition of proliferation and induction of apoptosis on APL cells.
Next, the effects of ADV on NB4 and HL-60 cells differentiation were investigated. Increased expression levels of CD11b were observed after treatment with 0.25 µM ADV for 96 h (Fig. 1I). Morphological changes associated with myeloid differentiation were also evident in ADV-treated NB4 cells (Additional file 1: Fig. S1B). These results suggested a differentiation-induction effect of low concentration of ADV on APL cells.
PML-RARA expression of APL blocks promyelocyte differentiation, leading to the proliferation of leukemia cells [1, 3, 4]. In NB4 cells, the oncoprotein PML-RARA was significantly decreased after treatment with 5 µM ADV for 24 h, but no change was observed for PML (Fig. 2A), which is required for the formation of nuclear bodies [5, 6]. However, the level of PML-RARA were not affected in 5 µM ETV-treated cells. These results suggested that ADV could inhibit malignant growth of APL cells through degradation of PML-RARA (but not PML).
To gain insight into the mechanism of ADV’s efficacy in APL, RNA-seq was performed (Additional file 1: Fig. S2). In the 5 µM ADV-treated (24 h) versus vehicle-treated (control) NB4 cells, there were 9491 differentially expressed genes, 4904 upregulated, while 4587 downregulated (Fig. 2B). TRIB3, which reportedly could promote rapid APL progression and all-trans retinoic acid resistance by stabilizing PML-RARa and high TWIST1 expression [7, 8], ranked #1 in the list of downregulated genes in ADV-treated versus control NB4 cells (Fig. 2C). In line with this, TRIB3 protein was significantly decreased after treatment with 5 µM ADV (Fig. 2A). Gene ontology analysis revealed a significant decrease in the biological processes of the GO categories “ribosome biogenesis” (Additional file 1: Fig. S1C). Similarly, using KEGG pathway analysis, ribosome protein genes were significantly downregulated by ADV. mTOR signaling pathway was inhibited by ADV via decreasing the phosphorylation of mTOR (Fig. 2D). On the contrary, the p53 signaling pathway, which could be inhibited by increased TRIB3 in APL , was activated by ADV (Fig. 2E).
Taken together, the present study demonstrated that ADV exhibited powerful inhibitory effects on APL. More importantly, our study uncovered a novel mechanism of ADV inhibiting APL, which was mediated, at least in part, by inducing cell differentiation and apoptosis via inhibition of TRIB3, and degradation of the oncoprotein PML-RARA.
Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave CJ, Hills RK, et al. Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice. Blood. 2018;131(6):636–48.
Luo X, Zhong L, Yu L, Xiong L, Dan W, Li J, et al. TRIB3 destabilizes tumor suppressor PPARalpha expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia. Life Sci. 2020;257:118021.
Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B, et al. TRIB3 promotes APL progression through stabilization of the oncoprotein PML-RARalpha and inhibition of p53-mediated senescence. Cancer Cell. 2017;31(5):697–710.
This work was supported by grants from the National Natural Science Foundation of China (Grant No. 81400107 and Grant No. 81802571), and Zhejiang Medical and Health Science and Technology Project (2019RC039 and 2022RC154).
Xubo Gong and Piaoping Kong contributed equally to this work
Authors and Affiliations
Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310000, Zheijang, People’s Republic of China
Xubo Gong, Piaoping Kong, Lin Wang, Yiwen Sang, Xiang Li, Zhihua Tao & Weiwei Liu
Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, Zheijang, People’s Republic of China
Teng Yu & Xibin Xiao
Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, USA
XG, WL, ZT and BZ were the principal investigators. XG and PK performed most of the experiments. TY, XX, LW, YS, and XL performed clinical analysis and critical review of the manuscript, and XG wrote the manuscript. All authors read and approved the final manuscript.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Gong, X., Kong, P., Yu, T. et al. Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA.
Exp Hematol Oncol11, 103 (2022). https://doi.org/10.1186/s40164-022-00355-1